TY  - JOUR
AU  - Gonzalez-Cao, Maria
AU  - Morán, Teresa
AU  - Dalmau, Judith
AU  - Garcia-Corbacho, Javier
AU  - Bracht, Jillian W P
AU  - Bernabe, Reyes
AU  - Juan, Oscar
AU  - de Castro, Javier
AU  - Blanco, Remei
AU  - Drozdowskyj, Ana
AU  - Argilaguet, Jordi
AU  - Meyerhans, Andreas
AU  - Blanco, Julia
AU  - Prado, Julia G
AU  - Carrillo, Jorge
AU  - Clotet, Bonaventura
AU  - Massuti, Bartomeu
AU  - Provencio, Mariano
AU  - Molina-Vila, Miguel A
AU  - Mayo de Las Casa, Clara
AU  - Garzon, Monica
AU  - Cao, Peng
AU  - Huang, Chung-Ying
AU  - Martinez-Picado, Javier
AU  - Rosell, Rafael
PY  - 2020
DO  - 10.1001/jamaoncol.2020.0465
UR  - http://hdl.handle.net/10668/15347
T2  - JAMA oncology
AB  - Therapies targeting the programmed cell death 1 (PD-1) receptor or its ligand (PD-L1), such as the humanized monoclonal antibody durvalumab, have shown durable clinical responses in several tumor types. However, concerns about the safety and...
LA  - en
KW  - Adult
KW  - Aged
KW  - Antibodies, Monoclonal
KW  - Antineoplastic Agents, Immunological
KW  - Female
KW  - HIV Infections
KW  - HIV-1
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Neoplasms
KW  - Treatment Outcome
TI  - Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection: The Phase 2 DURVAST Study.
TY  - research article
VL  - 6
ER  -